EMEA-002438-PIP02-19-M01
Key facts
| Active substance |
Rilzabrutinib
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0272/2021
|
| PIP number |
EMEA-002438-PIP02-19-M01
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of immune thrombocytopenia
|
| Route(s) of administration |
|
| Contact for public enquiries |
Principia Biopharma, Inc.
Tel. +1 6504167700 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|